202 related articles for article (PubMed ID: 19344276)
1. Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS.
Wu R; Wang H; Xia X; Zhou H; Liu C; Castro M; Xu Z
Antioxid Redox Signal; 2009 Jul; 11(7):1523-34. PubMed ID: 19344276
[TBL] [Abstract][Full Text] [Related]
2. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.
Wang H; Yang B; Qiu L; Yang C; Kramer J; Su Q; Guo Y; Brown RH; Gao G; Xu Z
Hum Mol Genet; 2014 Feb; 23(3):668-81. PubMed ID: 24108104
[TBL] [Abstract][Full Text] [Related]
3. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice.
Towne C; Raoul C; Schneider BL; Aebischer P
Mol Ther; 2008 Jun; 16(6):1018-25. PubMed ID: 18414477
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.
Wang LJ; Lu YY; Muramatsu S; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Matsushita T; Hanazono Y; Kume A; Nagatsu T; Ozawa K; Nakano I
J Neurosci; 2002 Aug; 22(16):6920-8. PubMed ID: 12177190
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.
Towne C; Setola V; Schneider BL; Aebischer P
Mol Ther; 2011 Feb; 19(2):274-83. PubMed ID: 21102563
[TBL] [Abstract][Full Text] [Related]
6. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
Xia X; Zhou H; Huang Y; Xu Z
Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
[TBL] [Abstract][Full Text] [Related]
7. Current developments in gene therapy for amyotrophic lateral sclerosis.
Scarrott JM; Herranz-MartÃn S; Alrafiah AR; Shaw PJ; Azzouz M
Expert Opin Biol Ther; 2015 Jul; 15(7):935-47. PubMed ID: 25959569
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.
Towne C; Aebischer P
Methods Mol Biol; 2009; 555():87-108. PubMed ID: 19495690
[TBL] [Abstract][Full Text] [Related]
9. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
[TBL] [Abstract][Full Text] [Related]
10. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
[TBL] [Abstract][Full Text] [Related]
11. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.
Raoul C; Abbas-Terki T; Bensadoun JC; Guillot S; Haase G; Szulc J; Henderson CE; Aebischer P
Nat Med; 2005 Apr; 11(4):423-8. PubMed ID: 15768028
[TBL] [Abstract][Full Text] [Related]
13. Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis.
Nanou A; Higginbottom A; Valori CF; Wyles M; Ning K; Shaw P; Azzouz M
Mol Ther; 2013 Aug; 21(8):1486-96. PubMed ID: 23732987
[TBL] [Abstract][Full Text] [Related]
14. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.
Nizzardo M; Simone C; Falcone M; Riboldi G; Rizzo F; Magri F; Bresolin N; Comi GP; Corti S
Cell Mol Life Sci; 2012 May; 69(10):1641-50. PubMed ID: 22094924
[TBL] [Abstract][Full Text] [Related]
15. AAV6-mediated gene silencing fALS short.
Mandel RJ; Lowenstein PR; Byrne BJ
Mol Ther; 2011 Feb; 19(2):231-3. PubMed ID: 21289637
[No Abstract] [Full Text] [Related]
16. [Gene therapy of ALS with RNA interference].
Yokota T
Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates.
Borel F; Gernoux G; Cardozo B; Metterville JP; Toro Cabrera GC; Song L; Su Q; Gao GP; Elmallah MK; Brown RH; Mueller C
Hum Gene Ther; 2016 Jan; 27(1):19-31. PubMed ID: 26710998
[TBL] [Abstract][Full Text] [Related]
18. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.
Azzouz M; Ralph GS; Storkebaum E; Walmsley LE; Mitrophanous KA; Kingsman SM; Carmeliet P; Mazarakis ND
Nature; 2004 May; 429(6990):413-7. PubMed ID: 15164063
[TBL] [Abstract][Full Text] [Related]
19. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy.
Acsadi G; Anguelov RA; Yang H; Toth G; Thomas R; Jani A; Wang Y; Ianakova E; Mohammad S; Lewis RA; Shy ME
Hum Gene Ther; 2002 Jun; 13(9):1047-59. PubMed ID: 12067438
[TBL] [Abstract][Full Text] [Related]
20. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons.
Yamashita T; Chai HL; Teramoto S; Tsuji S; Shimazaki K; Muramatsu S; Kwak S
EMBO Mol Med; 2013 Nov; 5(11):1710-9. PubMed ID: 24115583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
